WIN-Partners Co (TSE:3183) ROCE %: 12.43% (As of Mar. 2026)


TSE:3183 WIN-Partners Co Ltd TSE:3183
63 GF Score
Price 円1,285.00
GF Value 円1,522.55
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is WIN-Partners Co ROCE %?

WIN-Partners Co TSE:3183 +0.31% 63 ROCE % is 12.43% as of Mar. 2026. GuruFocus rates TSE:3183 with a GF Score™ of 63/100 and a GF Value™ of 円1,522.55 (Modestly Undervalued). The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. WIN-Partners Co's annualized ROCE % for the quarter that ended in Mar. 2026 was 12.43%.

WIN-Partners Co  (TSE:3183) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

WIN-Partners Co ROCE % Related Terms

WIN-Partners Co ROCE % Historical Data

* Premium members only.

The historical data trend for WIN-Partners Co's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

WIN-Partners Co ROCE % Chart

WIN-Partners Co Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.77 12.57 11.18 11.26 11.93

WIN-Partners Co Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.94 10.23 12.65 11.76 12.43
TSE:3183
63GF Score
WIN-Partners Co Ltd TSE:3183
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

WIN-Partners Co ROCE % Calculation

WIN-Partners Co's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Mar. 2026 )  (A: Mar. 2025 )(A: Mar. 2026 )
=3020.762/( ( (46620.372 - 21386.614) + (50632.099 - 25245.432) )/ 2 )
=3020.762/( (25233.758+25386.667)/ 2 )
=3020.762/25310.2125
=11.93 %

WIN-Partners Co's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Sep. 2025 )(Q: Mar. 2026 )
=3109.146/( ( (46525.896 - 21885.838) + (50632.099 - 25245.432) )/ 2 )
=3109.146/( ( 24640.058 + 25386.667 )/ 2 )
=3109.146/25013.3625
=12.43 %

(1) Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of 12.43% mean?
WIN-Partners Co (TSE:3183) has a ROCE % of 12.43% as of Mar. 2026.
Is WIN-Partners Co's ROCE % too high?
WIN-Partners Co's current ROCE % is 12.43%. The Medical Distribution industry median ROCE % is 8.92. WIN-Partners Co's value of 12.43% is 39.3% above this industry median. Overall, WIN-Partners Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does WIN-Partners Co's ROCE % compare to MCK and CAH?
WIN-Partners Co's ROCE % of 12.43% can be compared against companies in the Medical Distribution industry. The industry median ROCE % is 8.92. WIN-Partners Co's value of 12.43% is 39.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Medical Distribution company?
The median ROCE % among Medical Distribution companies is 8.92, based on 117 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. WIN-Partners Co's current ROCE % of 12.43% is 39.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median ROCE % is 8.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. WIN-Partners Co's current ROCE % is 12.43%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is WIN-Partners Co stock overvalued right now?
Based on GuruFocus' analysis, WIN-Partners Co (TSE:3183) is currently considered Modestly Undervalued. The stock's GF Value™ is 円1,522.55, compared to a current price of 円1,285.00 — trading 15.6% below its estimated fair value. The current ROCE % is 12.43% and 39.3% above the Medical Distribution industry median of 8.92. WIN-Partners Co's overall GF Score™ is 63/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For WIN-Partners Co (TSE:3183), the current ROCE % is 12.43% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is WIN-Partners Co (TSE:3183) Overvalued in 2026?

Based on GuruFocus' analysis, WIN-Partners Co stock appears to be undervalued. The current stock price of 円1,285.00 is trading 15.6% below its estimated GF Value™ of 円1,522.55. GuruFocus considers WIN-Partners Co to be Modestly Undervalued.

Key valuation signals for TSE:3183:

  • ROCE %: 12.43%
  • GF Value™: 円1,522.55 vs. price of 円1,285.00 (15.6% below fair value)
  • GF Score™: 63/100 with 3 warning signs
  • Industry Position: 39.3% above the Medical Distribution median

No single metric tells the full story. See the TSE:3183 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

WIN-Partners Co Business Description

Address 2-2-1 Kyobashi, Chuoku, 21st Floor, Kyobashi Edogrand, Tokyo, JPN, 104-0031
WIN-Partners Co Ltd is engaged in the healthcare sector. The company provides medical devices to Japan's medical institutions. Its products offerings are Cardiovascular device, Insulin Pump, X-ray Angio System, Carotid Artery Stent, Stent Graft, among others. The company operates only in one segment which is the medical equipment sales business.
63GF Score

Get the complete analysis for TSE:3183

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円1,285.00
Price
円1,522.55
GF Value